Payment overview · 2025
General Payments
$248.92
2 reported records · 2 companies
Healthcare provider profile · identity verified
Cynthia S. Lewin, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SERGEANT BLUFF, IA · NPI 1962467456
Verified facts
What the public records show
CMS Open Payments records show Cynthia S. Lewin, ARNP received $248.92 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.46 | 50.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.46 | 50.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.92 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 58 |
| Omeprazole | Omeprazole | 173 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 133 | 36 |
| Eliquis | Apixaban | 133 | 14 |
| Sertraline Hcl | Sertraline Hcl | 118 | 22 |
| Alprazolam | Alprazolam | 117 | 19 |
| Gabapentin | Gabapentin | 110 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 28 |
| Lisinopril | Lisinopril | 101 | 32 |
| Potassium Chloride | Potassium Chloride | 99 | 13 |
| Furosemide | Furosemide | 90 | 24 |
| Meloxicam | Meloxicam | 86 | 28 |
| Lorazepam | Lorazepam | 84 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 29 |
| Metformin Hcl | Metformin Hcl | 82 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 22 |
| Simvastatin | Simvastatin | 64 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 15 |
| Losartan Potassium | Losartan Potassium | 61 | 19 |
| Trazodone Hcl | Trazodone Hcl | 59 | 13 |
| Buspirone Hcl | Buspirone Hcl | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 15 |
| Prednisone | Prednisone | 51 | 40 |
| Carvedilol | Carvedilol | 50 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 18 |
| Topiramate | Topiramate | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 12 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Tegretol Xr | Carbamazepine | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Estradiol | Estradiol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Constulose | Lactulose | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Norethindrone-E.Estradiol-Iron | Norethindrone-E.Estradiol-Iron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.92 · 2 records | ABBVIE INC. | JARDIANCE, QULIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error